Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Adicet Bio, Inc.ACET · Entity 6860 | Director · President & CEO | June 19, 2026 | June 23, 2026 |
| BRAINSTORM CELL THERAPEUTICS INC.BCLI · Entity 7869 | Director | October 24, 2018 | December 21, 2018 |
| Karyopharm Therapeutics Inc.KPTI · Entity 781 | Director | May 21, 2026 | May 26, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Adicet Bio, Inc.
Report date June 19, 2026 · Filed June 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.10 · Expires 2036-06-18 | Direct | 55,000 |
Reported balance
After 2026-06-19 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-19 · Grant · Acquired 55,000 · Balance 55,000 F1: 1/48th of the shares shall vest on each of the next forty-eight (48) monthly anniversaries of the grant date with partial acceleration tied to certain performance milestones, provided that the Reporting Person maintains a service relationship with the Issuer as of the applicable vesting dates. |
Filing footnotes · ownership attribution and instrument terms
F1: 1/48th of the shares shall vest on each of the next forty-eight (48) monthly anniversaries of the grant date with partial acceleration tied to certain performance milestones, provided that the Reporting Person maintains a service relationship with the Issuer as of the applicable vesting dates.
BRAINSTORM CELL THERAPEUTICS INC.
Report date October 24, 2018 · Filed December 21, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 4,000 |
Reported balance
After 2018-10-24 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2018-10-24 · Gift · Disposed 121,558 · Balance 4,000 F1: These shares were previously reported as directly beneficially owned but on October 24, 2018 were gifted to an irrevocable trust for the benefit of the reporting person and other individuals. The reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. F2: Includes the November 30, 2018 acquisition of 2,000 shares by the reporting person, as reported on Form 4 filed November 30, 2018. |
| Common StockSEC Table I · non-derivative | IndirectBy The C. Schor Irrevocable Trust | 121,558 |
Reported balance
After 2018-10-24 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2018-10-24 · Gift · Acquired 121,558 · Balance 121,558 F1: These shares were previously reported as directly beneficially owned but on October 24, 2018 were gifted to an irrevocable trust for the benefit of the reporting person and other individuals. The reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were previously reported as directly beneficially owned but on October 24, 2018 were gifted to an irrevocable trust for the benefit of the reporting person and other individuals. The reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
F2: Includes the November 30, 2018 acquisition of 2,000 shares by the reporting person, as reported on Form 4 filed November 30, 2018.
Karyopharm Therapeutics Inc.
Report date May 21, 2026 · Filed May 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 15,508 |
Reported balance
After 2026-05-21 transaction · row 1
1 source rowRow 1 · 2026-05-21 · Grant · Acquired 15,508 · Balance 15,508 F1: Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan, as amended. RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest 100% on May 21, 2027; however, delivery of the shares is deferred until the earlier of (a) the date of the director's separation from service to Karyopharm Therapeutics Inc. and (b) a change-in-control event. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan, as amended. RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest 100% on May 21, 2027; however, delivery of the shares is deferred until the earlier of (a) the date of the director's separation from service to Karyopharm Therapeutics Inc. and (b) a change-in-control event.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 19, 2026 Filed Jun 23, 2026 22:51 UTC | Adicet Bio, Inc. ACET · Entity 6860 | GrantStock Option (Right to Buy) · Derivative | 55,000 | $0.00 Strike: $8.10 | $0.00 |
DisclosureSEC source: 0001340875-26-000007 · ownership.xml · derivative · entry 1 Schor Chen · CIK 0001340875 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 55,000 shares Expires 2036-06-18 F1 · derivative.exercise_date: 1/48th of the shares shall vest on each of the next forty-eight (48) monthly anniversaries of the grant date with partial acceleration tied to certain performance milestones, provided that the Reporting Person maintains a service relationship with the Issuer as of the applicable vesting dates. Read SEC document |
| May 21, 2026 Filed May 26, 2026 20:14 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | GrantCommon Stock | 15,508 | $0.00 | $0.00 |
DisclosureSEC source: 0001340875-26-000005 · ownership.xml · nonDerivative · entry 1 Schor Chen · CIK 0001340875 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,508 F1 · shares: Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan, as amended. RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest 100% on May 21, 2027; however, delivery of the shares is deferred until the earlier of (a) the date of the director's separation from service to Karyopharm Therapeutics Inc. and (b) a change-in-control event. Read SEC document |
| March 25, 2026 Filed Mar 27, 2026 20:12 UTC | Adicet Bio, Inc. ACET · Entity 6860 | GrantStock Option (Right to Buy) · Derivative | 468,555 | $0.00 Strike: $6.81 | $0.00 |
DisclosureSEC source: 0001340875-26-000003 · ownership.xml · derivative · entry 1 Schor Chen · CIK 0001340875 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 468,555 Underlying: Common Stock · 468,555 shares Expires 2036-03-24 F1 · derivative.exercise_date: (1) 1/48th of the shares shall vest on each of the next forty-eight (48) monthly anniversaries of the grant date, provided that the Reporting Person maintains a service relationship with the Issuer as of the applicable vesting dates. Read SEC document |
| January 24, 2026 Filed Jan 27, 2026 21:45 UTC | Adicet Bio, Inc. ACET · Entity 6860 | Tax withholdingCommon Stock | 1,755 | $8.44 | $14,812.20 |
DisclosureSEC source: 0001193125-26-024749 · ownership.xml · nonDerivative · entry 1 Schor Chen · CIK 0001340875 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,820 F1 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units and does not represent a sale by the Reporting Person. F2 · balance_after: Reflects a 1-for-16 reverse stock split effected by the Issuer on December 30, 2025. Read SEC document |
| May 28, 2025 Filed May 29, 2025 20:07 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | GrantNonstatutory Stock Option (right to buy) · Derivative | 4,600 | $0.00 Strike: $4.48 | $0.00 |
DisclosureSEC source: 0000950170-25-078938 · ownership.xml · derivative · entry 1 Schor Chen · CIK 0001340875 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,600 Underlying: Common Stock · 4,600 shares Expires 2035-05-27 F1 · derivative.exercise_price: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025. F1 · shares: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025. F2 · derivative.exercise_date: This option vests as to 100% of the underlying shares on May 28, 2026. F1 · derivative.underlying_shares: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025. F1 · balance_after: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025. Read SEC document |
| January 31, 2025 Filed Feb 4, 2025 21:41 UTC | Adicet Bio, Inc. ACET · Entity 6860 | GrantStock Option (Right to Buy) · Derivative | 763,829 | $0.00 Strike: $0.89 | $0.00 |
DisclosureSEC source: 0000950170-25-013607 · ownership.xml · derivative · entry 1 Schor Chen · CIK 0001340875 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 763,829 Underlying: Common Stock · 763,829 shares Expires 2035-01-30 F1 · derivative.exercise_date: 1/48th of the shares shall vest on each of the next forty-eight (48) monthly anniversaries of the grant date, provided that the Reporting Person maintains a service relationship with the Issuer as of the applicable vesting dates. Read SEC document |
| January 24, 2025 Filed Jan 28, 2025 21:29 UTC | Adicet Bio, Inc. ACET · Entity 6860 | Tax withholdingCommon Stock | 28,101 | $0.92 | $25,903.50 |
DisclosureSEC source: 0000950170-25-009843 · ownership.xml · nonDerivative · entry 1 Schor Chen · CIK 0001340875 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 137,201 F1 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units and does not represent a sale by the Reporting Person. Read SEC document |
| June 05, 2024 Filed Jun 7, 2024 20:09 UTC | Adicet Bio, Inc. ACET · Entity 6860 | GrantStock Option (Right to Buy) · Derivative | 1,770,427 | $0.00 Strike: $2.53 | $0.00 |
DisclosureSEC source: 0000950170-24-070618 · ownership.xml · derivative · entry 1 Schor Chen · CIK 0001340875 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,770,427 Underlying: Common Stock · 1,770,427 shares Expires 2034-01-25 F1 · derivative.exercise_date: 1/48th of the shares shall vest in forty-eight (48) equal monthly installaments following January 26, 2024, provided that the Reporting Person maintains a service relationship with the Issuer as of the applicable vesting dates. Read SEC document |
| May 29, 2024 Filed May 30, 2024 21:32 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | GrantNonstatutory Stock Option (right to buy) · Derivative | 69,000 | $0.00 Strike: $0.96 | $0.00 |
DisclosureSEC source: 0000950170-24-066786 · ownership.xml · derivative · entry 1 Schor Chen · CIK 0001340875 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,000 Underlying: Common Stock · 69,000 shares Expires 2034-05-28 F1 · derivative.exercise_date: This option vests as to 100% of the underlying shares on May 29, 2025. Read SEC document |
| January 24, 2024 Filed Jan 27, 2024 00:06 UTC | Adicet Bio, Inc. ACET · Entity 6860 | GrantStock Option (Right to Buy) · Derivative | 1,116,903 | $0.00 Strike: $2.40 | $0.00 |
DisclosureSEC source: 0000950170-24-008046 · ownership.xml · derivative · entry 5 Schor Chen · CIK 0001340875 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,116,903 Underlying: Common Stock · 1,116,903 shares Expires 2034-01-23 F5 · derivative.exercise_date: 1/48th of the shares shall vest on each of the next forty-eight (48) monthly anniversaries of the grant date, provided that the Reporting Person maintains a service relationship with the Issuer as of the applicable vesting dates. Read SEC document |
| January 24, 2024 Filed Jan 27, 2024 00:06 UTC | Adicet Bio, Inc. ACET · Entity 6860 | GrantCommon Stock | 70,300 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-008046 · ownership.xml · nonDerivative · entry 2 Schor Chen · CIK 0001340875 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 208,771 F2 · shares: The Reporting Person was issued RSUs. Each RSU represents a contingent right to receive one share of Common Stock. The RSUs shall vest in three (3) annual installments, with the first tranche vesting on January 24, 2025. The RSUs may be settled only by delivering shares of Common Stock, and thus, the grant is being reported in Table I as allowed per SEC guidance. Read SEC document |
| January 24, 2024 Filed Jan 27, 2024 00:06 UTC | Adicet Bio, Inc. ACET · Entity 6860 | Tax withholdingCommon Stock | 15,290 | $2.40 | $36,696.00 |
DisclosureSEC source: 0000950170-24-008046 · ownership.xml · nonDerivative · entry 1 Schor Chen · CIK 0001340875 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 138,471 F1 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units and does not represent a sale by the Reporting Person. Read SEC document |
| October 02, 2023 Filed Oct 3, 2023 00:16 UTC | Adicet Bio, Inc. ACET · Entity 6860 | Tax withholdingCommon Stock | 23,208 | $1.37 | $31,794.96 |
DisclosureSEC source: 0001209191-23-051259 · doc4.xml · nonDerivative · entry 5 Schor Chen · CIK 0001340875 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 153,761 F5 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units and does not represent a sale by the Reporting Person. Read SEC document |
| October 02, 2023 Filed Oct 3, 2023 00:16 UTC | Adicet Bio, Inc. ACET · Entity 6860 | PurchaseCommon Stock | 5,500 | $1.33 | $7,339.75 |
DisclosureSEC source: 0001209191-23-051259 · doc4.xml · nonDerivative · entry 4 Schor Chen · CIK 0001340875 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 43,469 F1 · kind: The transactions reported herein were matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). The Reporting Person will promptly and voluntarily disgorge to the Issuer the full amount of the resulting statutory profit calculated pursuant to Section 16(b) of the Exchange Act. F4 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions in prices ranging from $1.32 to $1.35, inclusive. Full information regarding the number of shares purchased at each separate price can be furnished to the SEC staff upon request. F2 · ownership.nature: Represents shares held directly by The I. Schor IRRV Trust, an irrevocable family trust having an independent trustee. Read SEC document |
| September 29, 2023 Filed Oct 3, 2023 00:16 UTC | Adicet Bio, Inc. ACET · Entity 6860 | SaleCommon Stock | 5,500 | $1.36 | $7,480.55 |
DisclosureSEC source: 0001209191-23-051259 · doc4.xml · nonDerivative · entry 3 Schor Chen · CIK 0001340875 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 176,969 F1 · kind: The transactions reported herein were matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). The Reporting Person will promptly and voluntarily disgorge to the Issuer the full amount of the resulting statutory profit calculated pursuant to Section 16(b) of the Exchange Act. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $1.33 to $1.38, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the Securities and Exchange Commission ("SEC") staff upon request. Read SEC document |
| September 28, 2023 Filed Oct 3, 2023 00:16 UTC | Adicet Bio, Inc. ACET · Entity 6860 | PurchaseCommon Stock | 5,500 | $1.42 | $7,810.00 |
DisclosureSEC source: 0001209191-23-051259 · doc4.xml · nonDerivative · entry 2 Schor Chen · CIK 0001340875 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 182,469 F1 · kind: The transactions reported herein were matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). The Reporting Person will promptly and voluntarily disgorge to the Issuer the full amount of the resulting statutory profit calculated pursuant to Section 16(b) of the Exchange Act. Read SEC document |
| September 28, 2023 Filed Oct 3, 2023 00:16 UTC | Adicet Bio, Inc. ACET · Entity 6860 | SaleCommon Stock | 5,500 | $1.42 | $7,810.00 |
DisclosureSEC source: 0001209191-23-051259 · doc4.xml · nonDerivative · entry 1 Schor Chen · CIK 0001340875 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 37,969 F1 · kind: The transactions reported herein were matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). The Reporting Person will promptly and voluntarily disgorge to the Issuer the full amount of the resulting statutory profit calculated pursuant to Section 16(b) of the Exchange Act. F2 · ownership.nature: Represents shares held directly by The I. Schor IRRV Trust, an irrevocable family trust having an independent trustee. Read SEC document |
| August 14, 2023 Filed Aug 16, 2023 22:11 UTC | Adicet Bio, Inc. ACET · Entity 6860 | GrantStock Option (Right to Buy) · Derivative | 384,900 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001209191-23-046103 · doc4.xml · derivative · entry 12 Schor Chen · CIK 0001340875 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 384,900 Underlying: Common Stock · 384,900 shares Expires 2033-01-23 F4 · derivative.exercise_price: The exercise price of the option is $2.14 per share, representing the fair market value per share of the Issuer's Common Stock on the Effective Date; provided that the repriced option will revert to its original exercise price if, prior to the first anniversary of the Effective Date, (a) the Reporting Person's employment is terminated by the Issuer with cause or by the Reporting Person or (b) the option is exercised. F2 · kind: On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 14, 2023 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F2 · price: On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 14, 2023 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F9 · derivative.exercise_date: The shares subject to this option shall vest in forty-eight (48) equal installments on each monthly anniversary following January 24, 2023, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| August 14, 2023 Filed Aug 16, 2023 22:11 UTC | Adicet Bio, Inc. ACET · Entity 6860 | Disposition to issuerStock Option (Right to Buy) · Derivative | 384,900 | $0.00 Strike: $9.05 | $0.00 |
DisclosureSEC source: 0001209191-23-046103 · doc4.xml · derivative · entry 11 Schor Chen · CIK 0001340875 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 384,900 shares Expires 2033-01-23 F2 · kind: On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 14, 2023 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F2 · price: On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 14, 2023 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F9 · derivative.exercise_date: The shares subject to this option shall vest in forty-eight (48) equal installments on each monthly anniversary following January 24, 2023, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| August 14, 2023 Filed Aug 16, 2023 22:11 UTC | Adicet Bio, Inc. ACET · Entity 6860 | GrantStock Option (Right to Buy) · Derivative | 295,000 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001209191-23-046103 · doc4.xml · derivative · entry 10 Schor Chen · CIK 0001340875 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 295,000 Underlying: Common Stock · 295,000 shares Expires 2032-01-06 F4 · derivative.exercise_price: The exercise price of the option is $2.14 per share, representing the fair market value per share of the Issuer's Common Stock on the Effective Date; provided that the repriced option will revert to its original exercise price if, prior to the first anniversary of the Effective Date, (a) the Reporting Person's employment is terminated by the Issuer with cause or by the Reporting Person or (b) the option is exercised. F2 · kind: On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 14, 2023 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F2 · price: On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 14, 2023 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F8 · derivative.exercise_date: The shares subject to this option shall vest in forty-eight (48) equal installments on each monthly anniversary following January 7, 2022, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| August 14, 2023 Filed Aug 16, 2023 22:11 UTC | Adicet Bio, Inc. ACET · Entity 6860 | Disposition to issuerStock Option (Right to Buy) · Derivative | 295,000 | $0.00 Strike: $15.52 | $0.00 |
DisclosureSEC source: 0001209191-23-046103 · doc4.xml · derivative · entry 9 Schor Chen · CIK 0001340875 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 295,000 shares Expires 2032-01-06 F2 · kind: On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 14, 2023 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F2 · price: On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 14, 2023 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F8 · derivative.exercise_date: The shares subject to this option shall vest in forty-eight (48) equal installments on each monthly anniversary following January 7, 2022, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| August 14, 2023 Filed Aug 16, 2023 22:11 UTC | Adicet Bio, Inc. ACET · Entity 6860 | GrantStock Option (Right to Buy) · Derivative | 421,600 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001209191-23-046103 · doc4.xml · derivative · entry 8 Schor Chen · CIK 0001340875 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 421,600 Underlying: Common Stock · 421,600 shares Expires 2031-02-11 F4 · derivative.exercise_price: The exercise price of the option is $2.14 per share, representing the fair market value per share of the Issuer's Common Stock on the Effective Date; provided that the repriced option will revert to its original exercise price if, prior to the first anniversary of the Effective Date, (a) the Reporting Person's employment is terminated by the Issuer with cause or by the Reporting Person or (b) the option is exercised. F2 · kind: On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 14, 2023 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F2 · price: On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 14, 2023 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F7 · derivative.exercise_date: The shares subject to this option shall vest in forty-eight (48) equal installments on each monthly anniversary following February 12, 2021, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| August 14, 2023 Filed Aug 16, 2023 22:11 UTC | Adicet Bio, Inc. ACET · Entity 6860 | Disposition to issuerStock Option (Right to Buy) · Derivative | 421,600 | $0.00 Strike: $16.82 | $0.00 |
DisclosureSEC source: 0001209191-23-046103 · doc4.xml · derivative · entry 7 Schor Chen · CIK 0001340875 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 421,600 shares Expires 2031-02-11 F2 · kind: On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 14, 2023 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F2 · price: On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 14, 2023 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F7 · derivative.exercise_date: The shares subject to this option shall vest in forty-eight (48) equal installments on each monthly anniversary following February 12, 2021, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| August 14, 2023 Filed Aug 16, 2023 22:11 UTC | Adicet Bio, Inc. ACET · Entity 6860 | GrantStock Option (Right to Buy) · Derivative | 240,000 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001209191-23-046103 · doc4.xml · derivative · entry 6 Schor Chen · CIK 0001340875 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 240,000 Underlying: Common Stock · 240,000 shares Expires 2031-01-12 F4 · derivative.exercise_price: The exercise price of the option is $2.14 per share, representing the fair market value per share of the Issuer's Common Stock on the Effective Date; provided that the repriced option will revert to its original exercise price if, prior to the first anniversary of the Effective Date, (a) the Reporting Person's employment is terminated by the Issuer with cause or by the Reporting Person or (b) the option is exercised. F2 · kind: On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 14, 2023 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F2 · price: On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 14, 2023 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F6 · derivative.exercise_date: The shares subject to this option shall vest in forty-eight (48) equal installments on each monthly anniversary following January 13, 2021, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| August 14, 2023 Filed Aug 16, 2023 22:11 UTC | Adicet Bio, Inc. ACET · Entity 6860 | Disposition to issuerStock Option (Right to Buy) · Derivative | 240,000 | $0.00 Strike: $13.27 | $0.00 |
DisclosureSEC source: 0001209191-23-046103 · doc4.xml · derivative · entry 5 Schor Chen · CIK 0001340875 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 240,000 shares Expires 2031-01-12 F2 · kind: On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 14, 2023 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F2 · price: On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 14, 2023 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F6 · derivative.exercise_date: The shares subject to this option shall vest in forty-eight (48) equal installments on each monthly anniversary following January 13, 2021, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| August 14, 2023 Filed Aug 16, 2023 22:11 UTC | Adicet Bio, Inc. ACET · Entity 6860 | GrantStock Option (Right to Buy) · Derivative | 872,111 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001209191-23-046103 · doc4.xml · derivative · entry 4 Schor Chen · CIK 0001340875 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 872,111 Underlying: Common Stock · 872,111 shares Expires 2030-09-16 F4 · derivative.exercise_price: The exercise price of the option is $2.14 per share, representing the fair market value per share of the Issuer's Common Stock on the Effective Date; provided that the repriced option will revert to its original exercise price if, prior to the first anniversary of the Effective Date, (a) the Reporting Person's employment is terminated by the Issuer with cause or by the Reporting Person or (b) the option is exercised. F2 · kind: On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 14, 2023 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F2 · price: On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 14, 2023 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F5 · derivative.exercise_date: The shares subject to this option shall vest in forty-eight (48) equal installments on each monthly anniversary following September 17, 2020, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| August 14, 2023 Filed Aug 16, 2023 22:11 UTC | Adicet Bio, Inc. ACET · Entity 6860 | Disposition to issuerStock Option (Right to Buy) · Derivative | 872,111 | $0.00 Strike: $16.11 | $0.00 |
DisclosureSEC source: 0001209191-23-046103 · doc4.xml · derivative · entry 3 Schor Chen · CIK 0001340875 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 872,111 shares Expires 2030-09-16 F2 · kind: On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 14, 2023 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F2 · price: On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 14, 2023 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F5 · derivative.exercise_date: The shares subject to this option shall vest in forty-eight (48) equal installments on each monthly anniversary following September 17, 2020, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| August 14, 2023 Filed Aug 16, 2023 22:11 UTC | Adicet Bio, Inc. ACET · Entity 6860 | GrantStock Option (Right to Buy) · Derivative | 36,857 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001209191-23-046103 · doc4.xml · derivative · entry 2 Schor Chen · CIK 0001340875 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,857 Underlying: Common Stock · 36,857 shares Expires 2029-12-05 F4 · derivative.exercise_price: The exercise price of the option is $2.14 per share, representing the fair market value per share of the Issuer's Common Stock on the Effective Date; provided that the repriced option will revert to its original exercise price if, prior to the first anniversary of the Effective Date, (a) the Reporting Person's employment is terminated by the Issuer with cause or by the Reporting Person or (b) the option is exercised. F2 · kind: On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 14, 2023 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F2 · price: On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 14, 2023 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F3 · derivative.exercise_date: The shares subject to this option are fully vested and exercisable as of the date hereof. Read SEC document |
| August 14, 2023 Filed Aug 16, 2023 22:11 UTC | Adicet Bio, Inc. ACET · Entity 6860 | Disposition to issuerStock Option (Right to Buy) · Derivative | 36,857 | $0.00 Strike: $8.89 | $0.00 |
DisclosureSEC source: 0001209191-23-046103 · doc4.xml · derivative · entry 1 Schor Chen · CIK 0001340875 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 36,857 shares Expires 2029-12-05 F1 · derivative.exercise_price: Reflects 1-for-7 reverse stock split effected by the Issuer on September 15, 2020. F2 · kind: On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 14, 2023 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · shares: Reflects 1-for-7 reverse stock split effected by the Issuer on September 15, 2020. F2 · price: On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 14, 2023 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F3 · derivative.exercise_date: The shares subject to this option are fully vested and exercisable as of the date hereof. F1 · derivative.underlying_shares: Reflects 1-for-7 reverse stock split effected by the Issuer on September 15, 2020. Read SEC document |
| May 24, 2023 Filed May 25, 2023 20:11 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | GrantNonstatutory Stock Option (right to buy) · Derivative | 34,000 | $0.00 Strike: $2.50 | $0.00 |
DisclosureSEC source: 0001209191-23-032152 · doc4.xml · derivative · entry 1 Schor Chen · CIK 0001340875 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,000 Underlying: Common Stock · 34,000 shares Expires 2033-05-23 F1 · derivative.exercise_date: This option vests as to 100% of the underlying shares on May 24, 2024. Read SEC document |
| January 24, 2023 Filed Jan 26, 2023 21:05 UTC | Adicet Bio, Inc. ACET · Entity 6860 | GrantStock Option (Right to Buy) · Derivative | 384,900 | $0.00 Strike: $9.05 | $0.00 |
DisclosureSEC source: 0001209191-23-005033 · doc4.xml · derivative · entry 3 Schor Chen · CIK 0001340875 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 384,900 Underlying: Common Stock · 384,900 shares Expires 2033-01-23 F3 · derivative.exercise_date: 1/48th of the shares shall vest on each of the next forty-eight (48) monthly anniversaries of the grant date, provided that the Reporting Person maintains a service relationship with the Company as of the applicable vesting dates. Read SEC document |
| January 24, 2023 Filed Jan 26, 2023 21:05 UTC | Adicet Bio, Inc. ACET · Entity 6860 | GrantCommon Stock | 85,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-005033 · doc4.xml · nonDerivative · entry 1 Schor Chen · CIK 0001340875 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 176,969 F1 · shares: The Reporting Person was issued Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock. The RSUs shall vest in three (3) annual installments, with the first tranche vesting on January 24, 2024. The RSUs may be settled only by delivering shares of Common Stock, and thus, the grant is being reported in Table I as allowed per SEC guidance. Read SEC document |
| November 14, 2022 Filed Feb 15, 2023 02:09 UTC | Adicet Bio, Inc. ACET · Entity 6860 | GiftCommon Stock | 9,955 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-009588 · doc5.xml · nonDerivative · entry 10 Schor Chen · CIK 0001340875 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,000 Read SEC document |
| November 14, 2022 Filed Feb 15, 2023 02:09 UTC | Adicet Bio, Inc. ACET · Entity 6860 | GiftCommon Stock | 9,955 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-009588 · doc5.xml · nonDerivative · entry 9 Schor Chen · CIK 0001340875 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 43,469 F1 · ownership.nature: Represents shares held directly by The I. Schor IRRV Trust, an irrevocable family trust having an independent trustee. Read SEC document |
| November 10, 2022 Filed Nov 15, 2022 21:31 UTC | Adicet Bio, Inc. ACET · Entity 6860 | SaleCommon Stock | 30,000 | $20.06 | $601,920.00 |
DisclosureSEC source: 0001209191-22-057004 · doc4.xml · nonDerivative · entry 2 Schor Chen · CIK 0001340875 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 53,424 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $20.00 to $20.27, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F4 · ownership.nature: Represents shares held directly by The C. Schor IRRV Trust, an irrevocable family trust having an independent trustee. Read SEC document |
| November 10, 2022 Filed Nov 15, 2022 21:31 UTC | Adicet Bio, Inc. ACET · Entity 6860 | SaleCommon Stock | 9,955 | $21.03 | $209,321.79 |
DisclosureSEC source: 0001209191-22-057004 · doc4.xml · nonDerivative · entry 1 Schor Chen · CIK 0001340875 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,469 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $21.00 to $21.18, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the Securities and Exchange Commission ("SEC") staff upon request. Read SEC document |
| November 07, 2022 Filed Nov 9, 2022 21:05 UTC | Adicet Bio, Inc. ACET · Entity 6860 | SaleCommon Stock | 30,000 | $19.05 | $571,488.00 |
DisclosureSEC source: 0001209191-22-056193 · doc4.xml · nonDerivative · entry 1 Schor Chen · CIK 0001340875 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 83,424 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $19.00 to $19.24, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the Securities and Exchange Commission staff upon request. F3 · ownership.nature: Represents shares held directly by The C. Schor IRRV Trust, an irrevocable family trust having an independent trustee. Read SEC document |
| November 03, 2022 Filed Nov 4, 2022 21:23 UTC | Adicet Bio, Inc. ACET · Entity 6860 | SaleCommon Stock | 24,813 | $18.04 | $447,718.33 |
DisclosureSEC source: 0001209191-22-055828 · doc4.xml · nonDerivative · entry 2 Schor Chen · CIK 0001340875 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 113,424 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $18.00 to $18.25, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the Securities and Exchange Commission staff upon request. F2 · ownership.nature: Represents shares held directly by The C. Schor IRRV Trust, an irrevocable family trust having an independent trustee. Read SEC document |
| November 02, 2022 Filed Nov 4, 2022 21:23 UTC | Adicet Bio, Inc. ACET · Entity 6860 | SaleCommon Stock | 500 | $18.00 | $9,000.00 |
DisclosureSEC source: 0001209191-22-055828 · doc4.xml · nonDerivative · entry 1 Schor Chen · CIK 0001340875 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 138,237 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · ownership.nature: Represents shares held directly by The C. Schor IRRV Trust, an irrevocable family trust having an independent trustee. Read SEC document |
| October 17, 2022 Filed Feb 15, 2023 02:09 UTC | Adicet Bio, Inc. ACET · Entity 6860 | GiftCommon Stock | 26,712 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-009588 · doc5.xml · nonDerivative · entry 8 Schor Chen · CIK 0001340875 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 53,424 F1 · ownership.nature: Represents shares held directly by The I. Schor IRRV Trust, an irrevocable family trust having an independent trustee. Read SEC document |
| October 17, 2022 Filed Feb 15, 2023 02:09 UTC | Adicet Bio, Inc. ACET · Entity 6860 | GiftCommon Stock | 26,712 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-009588 · doc5.xml · nonDerivative · entry 7 Schor Chen · CIK 0001340875 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,045 Read SEC document |
| October 04, 2022 Filed Oct 4, 2022 21:22 UTC | Adicet Bio, Inc. ACET · Entity 6860 | Tax withholdingCommon Stock | 21,288 | $14.22 | $302,715.36 |
DisclosureSEC source: 0001209191-22-052383 · doc4.xml · nonDerivative · entry 1 Schor Chen · CIK 0001340875 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,424 F1 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units and does not represent a sale by the Reporting Person. Read SEC document |
| September 28, 2022 Filed Feb 15, 2023 02:09 UTC | Adicet Bio, Inc. ACET · Entity 6860 | GiftCommon Stock | 26,712 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-009588 · doc5.xml · nonDerivative · entry 6 Schor Chen · CIK 0001340875 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 26,712 F1 · ownership.nature: Represents shares held directly by The I. Schor IRRV Trust, an irrevocable family trust having an independent trustee. Read SEC document |
| September 28, 2022 Filed Feb 15, 2023 02:09 UTC | Adicet Bio, Inc. ACET · Entity 6860 | GiftCommon Stock | 26,712 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-009588 · doc5.xml · nonDerivative · entry 5 Schor Chen · CIK 0001340875 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,757 Read SEC document |
| September 27, 2022 Filed Feb 15, 2023 02:09 UTC | Adicet Bio, Inc. ACET · Entity 6860 | GiftCommon Stock | 26,712 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-009588 · doc5.xml · nonDerivative · entry 4 Schor Chen · CIK 0001340875 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,469 Read SEC document |
| September 27, 2022 Filed Feb 15, 2023 02:09 UTC | Adicet Bio, Inc. ACET · Entity 6860 | GiftCommon Stock | 26,712 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-009588 · doc5.xml · nonDerivative · entry 3 Schor Chen · CIK 0001340875 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 F1 · ownership.nature: Represents shares held directly by The I. Schor IRRV Trust, an irrevocable family trust having an independent trustee. Read SEC document |
| September 14, 2022 Filed Sep 16, 2022 21:51 UTC | Adicet Bio, Inc. ACET · Entity 6860 | SaleCommon Stock | 952 | $18.00 | $17,136.00 |
DisclosureSEC source: 0001209191-22-050372 · doc4.xml · nonDerivative · entry 1 Schor Chen · CIK 0001340875 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 138,737 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · ownership.nature: Represents shares held directly by The C. Schor IRRV Trust, an irrevocable family trust having an independent trustee. Read SEC document |
| September 13, 2022 Filed Sep 13, 2022 20:59 UTC | Adicet Bio, Inc. ACET · Entity 6860 | SaleCommon Stock | 3,371 | $18.01 | $60,713.40 |
DisclosureSEC source: 0001209191-22-049721 · doc4.xml · nonDerivative · entry 4 Schor Chen · CIK 0001340875 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 139,689 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $18.00 to $18.05, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F5 · ownership.nature: Represents shares held directly by The C. Schor IRRV Trust, an irrevocable family trust having an independent trustee. Read SEC document |
| September 13, 2022 Filed Feb 15, 2023 02:09 UTC | Adicet Bio, Inc. ACET · Entity 6860 | GiftCommon Stock | 26,712 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-009588 · doc5.xml · nonDerivative · entry 2 Schor Chen · CIK 0001340875 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 26,712 F1 · ownership.nature: Represents shares held directly by The I. Schor IRRV Trust, an irrevocable family trust having an independent trustee. Read SEC document |
| September 13, 2022 Filed Feb 15, 2023 02:09 UTC | Adicet Bio, Inc. ACET · Entity 6860 | GiftCommon Stock | 26,712 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-009588 · doc5.xml · nonDerivative · entry 1 Schor Chen · CIK 0001340875 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,757 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.